Calidi Biotherapeutics, Inc. (CLDI): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001855485 0001855485 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
How this was made
The 30-second read
Why it matters
The newest disclosed facts are the appointment of Dr. Sanders (Class III director, Audit Committee member), deferral of her initial equity award pending allocation review, board expansion from five to six, and removal of Scott Leftwich from the Audit Committee effective June 17, 2026.
Market read
This is a governance update with no disclosed operational or financial catalyst, so it is unlikely to drive a sustained repricing absent additional news.
What to watch
The board size increase and Audit Committee reshuffle could matter if it precedes upcoming audit/financial reporting events, but the filing provides no such linkage.
Background
The filing is an SEC Form 8-K (Item 5.02) reporting a director appointment and related governance/compensation mechanics.
Ticker impact
Calidi Biotherapeutics appointed Dr. Corazon (Corsee) Sanders as a Class III director and Audit Committee member, expanding the board to six.
Likely limited near-term impact; any reaction should be small unless investors interpret the change as signaling broader strategic/financial shifts.
The 8-K discloses director appointment mechanics and committee membership, plus removal of Scott Leftwich from the Audit Committee, without any new earnings, trial, financing, or regulatory outcome.
Market effects
Minimal; this is company-specific governance rather than a sector-wide regulatory/clinical development.
Minimal; no geographic or cross-border transaction is described.
Minimal; no global partnership, financing, or regulatory action is disclosed.
Counterpoint
Investors may discount director/committee changes as routine, especially since the filing defers an initial equity award allocation rather than announcing any new compensation terms.
Key entities
- issuerCalidi Biotherapeutics, Inc.
NYSE American-listed company filing the 8-K; reports director and Audit Committee changes.
- directorDr. Corazon (Corsee) Sanders
Appointed Class III director (term expiring at 2029 annual meeting) and Audit Committee member; initial equity award deferred.
- directorScott Leftwich
Removed from the Audit Committee effective June 17, 2026, while continuing as a board member.
